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Objectives: We developed a population model that describes the ocular penetration and pharmacokinetics of
penciclovir in human aqueous humour and plasma after oral administration of famciclovir.
Methods: Fifty-three patients undergoing cataract surgery received a single oral dose of 500 mg of famciclovir
prior to surgery. Concentrations of penciclovir in both plasma and aqueous humour were measured by HPLC
with fluorescence detection. Concentrations in plasma and aqueous humour were fitted using a two-
compartment model (NONMEM software). Inter-individual and intra-individual variabilities were quantified
and the influence of demographics and physiopathological and environmental variables on penciclovir
pharmacokinetics was explored.
Results: Drug concentrations were fitted using a two-compartment, open model with first-order transfer
rates between plasma and aqueous humour compartments. Among tested covariates, creatinine clearance,
co-intake of angiotensin-converting enzyme inhibitors and body weight significantly influenced penciclovir
pharmacokinetics. Plasma clearance was 22.8+9.1 L/h and clearance from the aqueous humour was
8.2×1025 L/h. AUCs were 25.4+10.2 and 6.6+1.8 mg.h/mL in plasma and aqueous humour, respectively,
yielding a penetration ratio of 0.28+0.06. Simulated concentrations in the aqueous humour after adminis-
tration of 500 mg of famciclovir three times daily were in the range of values required for 50% growth inhib-
ition of non-resistant strains of the herpes zoster virus family.
Conclusions: Plasma and aqueous penciclovir concentrations showed significant variability that could only be
partially explained by renal function, body weight and comedication. Concentrations in the aqueous humour
were much lower than in plasma, suggesting that factors in the blood–aqueous humour barrier might
prevent its ocular penetration or that redistribution occurs in other ocular compartments.
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Introduction
Ocular herpes zoster (herpes zoster ophthalmicus) is a viral infec-
tious disease, which represents 15%–25% of all cases of zoster;
it is due to reactivation of latent varicella zoster virus (VZV) in the
first branch of the trigeminal nerve. Short- and long-term ocular
complications, such as uveitis, scleritis, stromal keratitis, neuro-
trophic keratitis and glaucoma, occur in 50%–70% of untreated
patients and may potentially lead to vision loss.1 – 3 Indeed, oph-
thalmic herpes zoster can cause pathological changes in the
ocular structures via several mechanisms: direct viral invasion,
secondary inflammation, alterations of autoimmune mechan-
isms and neurotrophic disorders.1 If instituted within 72 h of
the rash, systemic antiviral therapies reduce the incidence of
ocular complications.4
Famciclovir is an orally administered pro-drug of the antiviral
agent penciclovir; it is a nucleoside analogue active against VZV,
herpes simplex virus type I (HSV-1) and II (HSV-2) and Epstein–
Barr virus (EBV). After oral administration, famciclovir is quickly
deacetylated by intestinal and hepatic esterases and oxidized
# The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
J Antimicrob Chemother 2013; 68: 1635–1641
doi:10.1093/jac/dkt064 Advance Access publication 28 March 2013
1635
in the liver to penciclovir, and little or essentially no parent com-
pound is recovered from blood or urine.5,6 The absolute oral bio-
availability of penciclovir is between 70% and 75% and the time
to reach maximum concentrations ranges between 0.5 and
0.75 h after the dose.7 Penciclovir is extensively distributed and
,20% bound to plasma proteins over the therapeutic concentra-
tion range. It is mainly eliminated via the kidneys, by glomerular
filtration and tubular secretion, with an elimination half-life of
2 h in young healthy volunteers.5,8
The longer intracellular half-life of penciclovir triphosphate
and its lower potential toxicity, in addition to the emergence of
cases of aciclovir-resistant strains, allows it to be an efficacious
alternative to valaciclovir and aciclovir for the treatment of oph-
thalmic herpes zoster.9 Vitreous concentrations within the inhibi-
tory range for HSV and VZV have been reported in a small
study.10 However, the pharmacokinetic characteristics of pen-
ciclovir penetration in the human eye are still unknown.
The aim of the present study was to characterize the popula-
tion pharmacokinetics of penciclovir in plasma and aqueous
humour, and estimate its penetration into the eye after oral
administration of famciclovir. The population approach served
to quantify inter-individual variability and to identify potential
influential covariates.
Methods
Study data
Fifty-three adult patients undergoing cataract surgery were included.
Three patients provided drug level data that were used to determine
the limit of quantification of penciclovir in the aqueous humour and
the sampling schedule for the 50 subsequently included patients. Inclu-
sion criteria were age ≥18 years and Karnofsky score ≥60. Exclusion cri-
teria were pregnancy or breastfeeding, immunosuppression, shingles,
ocular infection or inflammation, retinal detachment and intraocular in-
jection of silicone oil. A single dose of 500 mg of famciclovir was adminis-
tered to each patient at various times prior to cataract surgery (range
1.1–18.5 h). The compound was administered to fasting patients in the
presence of their usual medication. A median of 3 (range 1–5) plasma
samples and a single aqueous humour sample were collected in each
patient between 1 and 19 h after drug intake. The Ethics Committee of
Geneva University Hospitals approved the protocol and all patients
gave written informed consent regarding participation in the study.
Analytical method
Blood samples were collected into heparinized tubes from the forearm
and plasma was obtained after immediate centrifugation of the
samples (3000 g at 48C for 10 min). Aqueous humour samples
(100 mL) were directly transferred into polypropylene tubes. Plasma and
aqueous humour samples were stored at 2208C until analysis.
Penciclovir analysis in aqueous humour and plasma was performed as
previously described.11 Briefly, plasma samples were purified by solid-
phase extraction using OasiswMCX (30 mg) cartridges, a polymeric
mixed-mode cation exchange and reversed-phase sorbent. Ganciclovir,
an antiviral drug structurally related to penciclovir, was used as an intern-
al standard. Owing to the low protein content, aqueous humour samples
were directly injected onto the HPLC system and no internal standard
was added.
The chromatographic equipment consisted of an Agilent 100 Series LC
system (Agilent, Paolo Alto, USA) with a quaternary pump, a vacuum
degasser, an autosampler, a thermostated column compartment and
a fluorescence detector. Chromatographic conditions were the same
for the two biological fluids. Separation was performed by gradient
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Figure 1. Structural pharmacokinetic model for penciclovir plasma (P)
and aqueous humour (AH) concentrations.
Table 1. Derived pharmacokinetic parameters
Parameter Definition Formula
t1/2P (h) elimination half-life from plasma ln(2)/K20
CLP (L/h) plasma clearance K20 VP
AUCP (mg.h/L) area under the curve in plasma dose/CLP
t1/2AH (h) elimination half-life from aqueous
humour
ln(2)/K32
CLAH (L/h) clearance from aqueous humour K32 VAH
AUCAH (mg.h/L) AUC in aqueous humour (dose/CLAH)
(K23/K20)
Pratio coefficient of penetration into
aqueous humour
(K23 VP)/(K32 VAH)
Table 2. Demographic characteristics of the study population
Characteristic
Sex (n¼53), n (%)
male 22 (42)
female 31 (58)
Age (years) (n¼53)
mean+SD 77.3+13.3
median (range) 81 (30–98)
Body weight (kg) (n¼49)
mean+SD 69.6+15.8
median (range) 68 (47–146)
BMI (kg/m2) (n¼42)
mean+SD 25.7+4.4
median (range) 25.1 (18.4–44.1)
CLCR (mL/min) (n¼38)
mean+SD 57.5+32.2
median (range) 48.8 (24.4–163.4)
Comedication, n (%)
anti-inflammatory agents 17 (32)
ACE inhibitors 15 (28)
diuretics 16 (30)
b-blockers 10 (19)
proton pump inhibitors 12 (23)
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elution on a Zorbax SB-aqC18 (100 mm×2.1 mm) column with a mobile
phase consisting of a mixture of acetonitrile and 50 mM phosphate
buffer containing 5 mM sodium octanesulfonate, pH 2.0, at a flow rate
0.3 mL/min. Detection was fluorimetric with emission and excitation wave-
lengths set at 360 and 253 nm, respectively. The column temperature was
fixed at 208C. Twenty microlitres was injected onto the HPLC system.
The limit of quantification (LOQ) was 0.1 mg/mL [coefficient of vari-
ation (CV) 8.8%] for plasma and 0.05 mg/mL for aqueous humour (CV
5.5%). Measured concentrations ,LOQ were set to LOQ/2 for pharmaco-
kinetic modelling (n¼7 in plasma and n¼1 in aqueous humour).
Population pharmacokinetic analysis
The time courses of penciclovir concentrations in plasma and aqueous
humour were fitted using non-linear mixed-effect modelling (NONMEM)
and the relationship between parameter estimates and available covari-
ates was investigated.
Basic model
A two-compartment, open model with first-order transfer rates between
plasma and aqueous humour was used to describe the pharmacokinetics
of penciclovir (Figure 1). Basic estimated parameters were the absorption
rate constant (Ka), the elimination rate constant (K20), the transfer rate
constants between plasma and aqueous humour (K23 and K32) and the
volume of distribution in plasma (VP). The volume of distribution of the
aqueous humour (VAH) was fixed to 200 mL according to the true physio-
logical intracameral volume.12 Due to its small volume, aqueous humour
incorporates extremely reduced amounts of drug from plasma and con-
sequently does not affect the concentration–time profile in plasma. Elim-
ination from the aqueous humour could not be distinguished from
redistribution to the plasma compartment, and bidirectional first-order
exchange between plasma and aqueous humour was thus chosen to de-
scribe penciclovir flow across the blood–aqueous barrier.13
The following parameters were derived from the final individual
Bayesian estimates: penciclovir clearance (CL), AUC and elimination half-
life (t1/2) in plasma and aqueous humour (Table 1). The penetration of
penciclovir in the eye was described by the penetration coefficient
(Pratio), defined as AUCAH/AUCP. This coefficient reflects the aqueous-
to-plasma concentration ratio that occurs transiently when the concen-
tration in the aqueous humour reaches its peak value. As no intravenous
famciclovir was administered, volumes of distribution, CLs and AUCs re-
present apparent values.
The inter-individual variability in the population parameters was mod-
elled assuming exponential error models, using ui¼u .exp(hi), where ui is
the pharmacokinetic parameter of the ith individual, u is the average
population value and hi is a random effect, assumed to be normally dis-
tributed with a mean of zero and a variance v2. Residual (intra-individual)
variability was estimated for plasma and humour data and modelled
using an exponential error model of the form Cij,obs¼Cij,pred exp(1ij), with
Cij,obs and Cij,pred representing observed and predicted concentrations of
the ith subject at time j, respectively, and 1ij the residual error, assumed
to be normally distributed with a mean of zero and a variance s2.
Table 3. Final population pharmacokinetic parameters for penciclovir in 53 patients and validation from 2000 bootstrapped samples
Parameters
Population model
(n¼53 patients) Bootstrap validation (n¼2000 samples)
estimate SE (%)a mean SE (%)a 95% CI
Ka (h
21) 1.86 — 1.86 — —
K20 (h
21) 0.25 4 0.25 4 0.23–0.27
K23 (h
21) 2.59×1027 9 2.50×1027 9 2.00×1027–2.90×1027
K32 (h
21) 0.41 9 0.40 9 0.33–0.47
VP (L) 86.2 6 87.2 5 79.1–98.0
VAH (L) 2.0×1024 — 2.0×1024 — —
uCLCR (h
21)b 0.07 29 0.07 31 0.03–0.12
uACE inhibitors (h
21)b 0.06 32 0.04 35 0.01–0.08
uBW
c 1.01 18 1.08 18 0.70–1.44
v (K20) (CV %)
d 21 48f 20 47f 15–24
v (VP) (CV %)
d 14 110f 17 83f 4–27
sP (CV %)
e 24 61f 22 60f 15–30
sAH (CV %)
e 28 48f 28 47f 23–35
Final model:
TVK20¼K20+uCLCR×(CLCR248.8)/48.82uACE inhibitors×ACE inhibitors
TVVP¼VP×[1+uBW×(BW268)/68]
TV, typical population value; P, plasma; AH, aqueous humour; Ka, mean absorption rate constant; K20, mean apparent elimination rate constant; K23,
mean apparent distribution rate constant from P to AH; K32, mean apparent elimination rate constant from AH to P; VP, mean apparent volume of
distribution in plasma; VAH, mean apparent volume of distribution in the aqueous humour; CLCR, creatinine clearance (with median value of
48.8 mL/min); BW, body weight (with median value of 68 kg).
aStandard errors of the estimates (SE), defined as SE/estimate and expressed as percentages.
bRelative influence of CLCR and ACE inhibitor intake (0/1) on K20.
cRelative influence of BW on VP.
dEstimate of between-subject variability, expressed as CV %.
eEstimate of residual variability, expressed as CV %.
fStandard errors of the CVs, taken as
p
(SE/estimate) and expressed as a percentage.
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Covariate model
Available covariates were age, body weight, body mass index (BMI),
creatinine clearance (CLCR), gender and comedication. Only comedica-
tions likely to influence renal elimination or drug absorption were
tested. CLCR was estimated according to the Cockcroft–Gault equa-
tion.14 Dichotomous variables were coded 0/1 and missing CLCR and
body weight were set to median values. Analyses of covariate effects
were performed in two main steps: (i) the relationships between indi-
vidual parameters and covariates were first analysed with the non-
parametric Mann–Whitney test for categorical covariates and the
Spearman correlation coefficient for continuous covariates (software
SYSTAT version 10, Systat Software Inc., Chicago, IL, USA); and (ii) sig-
nificant covariates (P,0.05) were then integrated in the population
model using linear or non-linear functions as appropriate, centred on
the median value.
Parameter estimation and model selection
NONMEMw15 (version 7.2, NM-TRAN, version II) was used with the FOCE
INTERACTION method to fit the data. The minimum objective function
value (DOF) provided by NONMEMw (22 log likelihood, approximate x2
distribution) was used to discriminate between models using the likeli-
hood ratio test. A model was considered superior to another nested
model when the OF value was reduced by at least 3.84 points
(P,0.05). Covariate analysis comprised forward selection of influential
factors followed by backward deletion. Covariates were retained in the
final model at the statistical level of P,0.01. Model assessment was
based on diagnostic plots (goodness-of-fit plots and normalized predic-
tion distribution errors) along with standard errors and correlation
matrix of parameter estimates, size of residual errors and h shrinkage.
Model validation
The stability and performance of the final population pharmacokinetic
model were validated by the bootstrap method using 2000 bootstrap
samplings with replacement. The final population pharmacokinetic
model was fitted repeatedly to the 2000 bootstrapped samples and phar-
macokinetic parameters were calculated for each dataset. The mean,
standard error and 95% CI of each parameter obtained with the boot-
strapped data were then compared with the corresponding parameters
obtained with the original dataset. The statistical analysis was performed
using Perl-speaks-NONMEM version 3.2.4 (http://psn.sourceforge.net/). The
final model was also validated using visual predictive check (VPC). Using
the parameter values of the final population pharmacokinetic model, we
simulated data for 1000 individuals and generated 2.5th, 50th and
97.5th percentiles. The observed concentrations were plotted against the
95% prediction interval (PI95%) of the simulated dataset at each timepoint
and visually compared. Figures were generated using GraphPad Prism
(version 4.00 for Windows, GraphPad Software, San Diego, CA, USA; www.
graphpad.com).
Results
A total of 164 plasma samples and 53 aqueous humour samples
were collected. Penciclovir concentration ranged from 0.05 to
7.26 mg/mL in plasma and from 0.025 to 1.21 mg/mL in
aqueous humour. Demographic characteristics of the study
sample are described in Table 2.
A two-compartment model with first-order transfer rates
adequately described the pharmacokinetics of penciclovir in
aqueous humour and plasma. Because of a lack of data in the
Table 4. Mean and inter-individual variability of parameters derived from the final model
t1/2P (h) CLP (L/h) AUCp (mg.h/mL) t1/2AH (h) CLAH (L/h) AUCAH (mg.h/mL) Pratio
Mean+SD 2.9+0.8 22.8+9.1 25.4+10.2 1.7 8.2×1025 6.6+1.8 0.28+0.06
CV % 28% 40% 40% — — 28% 22%
Range 1.7–5.3 8.9–56 8.9–56.2 — — 3.8–12.2 0.18–0.54
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Figure 2. Penciclovir plasma (top panel) and aqueous humour (bottom
panel) concentrations (circles) after a 500 mg oral dose of famciclovir
in 53 patients. Continuous lines represent population predictions for
an 81-year-old person with a body weight of 68 kg and a CLCR of
48.8 mL/min (median values in the study sample). Broken lines show
the PI95% obtained from a simulated dataset of 1000 subjects.
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absorption phase, the absorption rate Ka could not be adequately
estimated and was fixed to 1.86 h21 according to the literature.16
Assignment of inter-individual variability on K20 (DOF¼2205;
P,0.0001) and VP (DOF¼266.5; P,0.0001) improved the fit,
but data did not support the estimation of inter-individual variabil-
ity on K23 or K32, in keeping with a single observation per patient in
the aqueous humour. Incorporating covariance between K20 and
VP slightly improved the fit (DOF¼27.3; P,0.01).
The statistical preliminary covariate analysis identified a sig-
nificant effect of age, CLCR and co-intake of an angiotensin-
converting enzyme (ACE) inhibitor on K20, as well as body
weight, BMI, age and sex on VP (P,0.001). All these covariates,
except for BMI (with an effect statistically not different from
body weight), were further tested for significance in the model.
In univariate analyses, a significant influence of age
(DOF¼224.1; P,0.001), CLCR (DOF¼211.1; P,0.001) and ACE
inhibitors (DOF¼25.0; P,0.05) on K20 was observed. Sex and
body weight did not significantly influence penciclovir elimination
(DOF,20.7). The inclusion of a body weight effect on VP
improved the fit (DOF¼219; P,0.001), but no other variable
showed any influence on this parameter. Multivariate analysis
identified CLCR and co-intake of an ACE inhibitor as significant
predictors of penciclovir elimination and an influence of body
weight on VP (DOF¼250.2; P,0.0001 compared with the
model without any covariates). The age effect on K20 did not
remain significant, as it was correlated to CLCR. Correlation
between K20 and VP did not remain statistically significant
either after inclusion of the covariates. Penciclovir elimination
(K20) was reduced by 41% in patients with severe renal impair-
ment (CLCR 20 mL/min) compared with those with a normal
renal function (CLCR 120 mL/min), which is further decreased by
17% and 29%, respectively, in the presence of an ACE inhibitor.
Upon body weight doubling, doubling of the volume of distribu-
tion is expected. Significant covariates explained 15% and 34%
of the variability in K20 and VP, respectively. The final population
pharmacokinetic parameters and results from the bootstrap
analysis are presented in Table 3. Secondary parameters
derived from the final model are summarized in Table 4. The
mean Pratio from plasma to aqueous humour was 28%, with in-
dividual values ranging from 18% to 54%. Goodness-of-fit plots
and VPC are depicted in Figures 2 and 3.
Simulated concentration–time profiles in plasma and in
aqueous humour after 500 mg of oral famciclovir three times
daily are depicted in Figure 4. Average minimal and maximal
concentrations (mg/mL) at steady-state were, respectively, 0.43
(PI95% 0.053–1.99) and 4.47 (PI95% 2.1–9.6) in plasma and
0.28 (PI95% 0.08–0.84) and 0.83 (PI95% 0.42–1.62) in aqueous
humour.
Discussion
The present study describes for the first time the penetration and
pharmacokinetics of penciclovir in the aqueous humour after oral
administration of famciclovir. Over recent years, particular inter-
est in the intraocular penetration of anti-infectious agents admi-
nistered orally has arisen from the growing incidence of ocular
infections resulting from the increasing number of transplant
and HIV patients. Oral administration is easy to perform and
may make it possible, according to the physico-chemical charac-
teristics of the molecule, to obtain therapeutic concentrations in
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Figure 3. Goodness-of-fit plots. Penciclovir plasma (top panels) and aqueous humour (bottom panels) population (left-hand panels) and individual
(right-hand panel) predictions versus observed concentrations in 53 patients.
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aqueous humour. The favourable pharmacokinetic profile of pen-
ciclovir compared with aciclovir and valaciclovir (higher oral bio-
availability, higher intracellular triphosphate concentration and
prolonged intracellular half-life) makes it a suitable alternative
for the treatment of various types of infections caused by
viruses of the herpes simplex family.17
The estimates of penciclovir plasma CL, volume of distribution
and half-life are in good agreement with previously reported
values.16 As expected, penciclovir elimination is markedly affected
by renal function.18 In addition, a significant influence of
co-administered ACE inhibitors was observed. The well-known
effect of these drugs on the filtration pressure might explain this
finding. The observed ACE effect might also have corrected a po-
tential bias in the estimation of true renal function, which might
have been over- or under-estimated by the Cockcroft–Gault ap-
proximation in some patients. In line with reported data, pen-
ciclovir is extensively distributed and its volume of distribution
is affected by body weight.5
Penciclovir exhibits several characteristics favourable to good
intraocular penetration: small molecular weight, low protein
binding and high volume of distribution. The average penetration
ratio of penciclovir in the eye was 28%, with a CV of 22% reflect-
ing variability in penciclovir volume of distribution. This penetra-
tion ratio is similar to the 28% (CV 32%) and 24% (CV 25%)
reported for penciclovir10 and aciclovir19 in the vitreous
humour, respectively. The much lower exposure in the aqueous
humour than in plasma suggests that penciclovir distribution
to this liquid might be regulated by efflux transport systems in
the blood–aqueous barrier that limit the ocular bioavailability
of systemically administered drugs.20 Maximal concentrations
in the aqueous humour were reached 4 h after drug intake,
whereas plasma peak levels were obtained in ,1 h. This delay
was dependent on the rate constant from aqueous humour to
plasma, whereas the concentration decrease in aqueous
humour paralleled that in plasma at later times (flip-flop kinetics,
with K32.K20). The apparent CL from aqueous humour of
1.37 mL/min is compatible with the reported rate of aqueous
humour secretion (1–3 mL/min) in humans.21 This might
suggest that penciclovir is mainly eliminated from the eyes by
the humour turnover.
Simulations of multiple doses of famciclovir based on the final
model show that no accumulation occurs in plasma or in the
aqueous humour. Owing to marked inter-individual variability,
a wide range of concentrations in plasma and the aqueous
humour can be observed. Higher concentrations in the aqueous
humour can be expected in overweight patients and in those pre-
senting an impaired renal function in particular, but other as yet
unknown factors influencing drug intraocular penetration might
also be involved.
Studies have demonstrated that oral administration of
500 mg of famciclovir three times daily leads to satisfactory
and sustained intracellular triphosphate concentrations and
represents an effective regimen in the treatment of cutaneous
or ophthalmic shingles.9,22,23 However, no clear relationship has
been established to date between penciclovir plasma levels,
intracellular triphosphate concentrations and antiviral efficacy.
The concentration of penciclovir required for inhibiting virus
growth in cell culture by 50% (IC50) varies considerably depend-
ing on assay type and infecting virus, with the IC50 ranging from
0.02 to 0.9 mg/mL for HSV-1, from 0.06 to 4.4 mg/mL for HSV-2,
from 0.8 to 4 mg/mL for VZV and from 1.5 to 3.1 mg/mL for
EBV.24 – 26 Based on such in vitro data, our model predicts that
plasma concentrations are within the range of inhibitory concen-
trations for susceptible virus. Aqueous concentrations are within
the range of IC50 values reported for HSV-1, HSV-2 and EBV and
in the lower range of IC50 values reported for VZV. Based on data
from Chong et al.,10 vitreous penciclovir concentrations of
patients receiving 500 mg of famciclovir three times a day
were within the range of simulated aqueous humour concentra-
tions in Figure 4 (same dosing regimen). Therefore, penciclovir
concentrations in aqueous and vitreous humours are expected
to be similar and within the range of the IC50 for HSV-1, HSV-2,
EBV or VZV, which are also involved in herpetic anterior uveitis
or acute retinal necrosis. Similar results were observed in
different studies comparing aqueous and vitreous humour
levels of different antibiotics after oral administration in
humans. For example, after oral administration of 400 mg of
ofloxacin, aqueous and vitreous humour levels were 1.54+0.27
and 1.77+0.24 mg/mL, respectively.27 Human aqueous and
vitreous humour levels of ciprofloxacin following oral
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Figure 4. Simulations of penciclovir in plasma (top panel) and in the
aqueous humour (bottom panel) after 500 mg of famciclovir three
times daily (6, 12 and 24 h) for an 81-year-old person with a body
weight of 68 kg and a CLCR of 48.8 mL/min (median values in the study
sample). The continuous line represents the population predictions and
the broken lines show the PI95%.
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administration of 1000 mg of ciprofloxacin were 0.59+0.06 and
0.64+0.06 mg/mL, respectively.28
Limitations of the present study need to be acknowledged.
First, the sample size was relatively modest and the statistical
power was limited, in particular with respect to the possible
role of comedication. Second, sample characteristics (a majority
of elderly patients, with impaired renal function and several
comedications) might not allow generalization of the results to
all patients for whom penciclovir treatment is intended. Third,
the fact that a single aqueous humour sample was collected
per patient prevented more precise investigation of variability
associated with transfers into and out of the aqueous humour.
In conclusion, famciclovir oral administration results in vari-
able plasma and ocular concentrations that are partially
explained by renal function, co-administration of ACE inhibitors
and body weight. The penetration ratio of penciclovir in the
aqueous humour is 28% (CV 22%), with peak concentration
reached 4 h after drug intake. Average concentrations of pen-
ciclovir in the aqueous humour after multiple dosing of 500 mg
of famciclovir three times daily are in the range of IC50 values
for non-resistant herpes zoster virus and in the low range of
IC50 values for varicella zoster virus, but the relationship
between concentrations in the aqueous humour and efficacy
needs to be further investigated.
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